Ask AI
ProCE Banner Activity

Reaching New Heights in Cardio–Renal–Metabolic Care: Optimizing Treatment to Elevate Patient Outcomes

Slideset

Expert-curated slides with best practices for providing guideline-directed medical therapy in cardio–renal–metabolic (CRM) care and the latest evidence supporting the use of SGLT2 inhibitors in patients with CRM conditions.

Released: March 11, 2026

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

This activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company.

Boehringer Ingelheim Pharmaceuticals, Inc.

Eli Lilly and Company

Target Audience

This activity is intended for internal medicine and other healthcare professionals involved in the management of patients with heart failure and/or CKD including physicians, nurse practitioners, and physician associates.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Recognize ongoing care gaps in the management of patients with cardio-renal–metabolic disease and the consequences of delayed therapeutic intervention

  • Interpret current and emerging evidence on the benefits of SGLT2 inhibitors across the cardio– renal–metabolic spectrum to support earlier initiation and sustained therapy

  • Develop patient-centered counseling approaches to effectively integrate SGLT2 inhibitors into individualized cardio–renal–metabolic care plans